Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Plas, Ellen Van Der

Arkansas Children'S Hospital Res Inst
United States

Identifying markers of abnormal neurocognitive trajectories during chemotherapy treatment of childhood acute lymphoblastic leukemia 5R37CA266135-04 Asad Umar, D.V.M., Ph.D.
Plas, Ellen Van Der

Arkansas Children'S Hospital Res Inst
United States

Identifying markers of abnormal neurocognitive trajectories during chemotherapy treatment of childhood acute lymphoblastic leukemia 5R37CA266135-04 Asad Umar, D.V.M., Ph.D.
Porter, Laura S

Duke University
United States

Couple Communication Skills Training for Advanced Cancer 5R01CA229425-05 Brennan Streck, Ph.D., RN, M.P.H.
Porter, Laura S

Duke University
United States

Couple Communication Skills Training for Advanced Cancer 5R01CA229425-05 Brennan Streck, Ph.D., RN, M.P.H.
Pozdeyev, Nikita

University Of Colorado Denver
United States

Genetic architecture of thyroid cancer and its clinical utility 5R21CA282380-02 Wendy Wang, Ph.D., M.Sc.
Prigerson, Holly Gwen

Weill Medical Coll Of Cornell Univ
United States

Behavioral and Psychosocial Effects on Study Outcomes in End-Stage Cancer Treatment (BEST End-Stage Cancer Study) 5R35CA197730-11 Brennan Streck, Ph.D., RN, M.P.H.
Prigerson, Holly Gwen

Weill Medical Coll Of Cornell Univ
United States

Behavioral and Psychosocial Effects on Study Outcomes in End-Stage Cancer Treatment (BEST End-Stage Cancer Study) 5R35CA197730-11 Brennan Streck, Ph.D., RN, M.P.H.
Punnen, Sanoj

University Of Miami School Of Medicine
United States

The Rigor and Clinical Utility of PSMA Enriched Extracellular Vesicles for Prostate Cancer Detection 5R01CA272766-03 Matthew Young, Ph.D.
Pyter, Leah M

Ohio State University
United States

Chemotherapy-induced circadian master clock disruptions and fatigue 3R01CA270372-03S1 Marjorie Perloff, M.D.
Pyter, Leah M

Ohio State University
United States

Chemotherapy-induced circadian master clock disruptions and fatigue 3R01CA270372-03S1 Marjorie Perloff, M.D.
Rajagopalan, Malolan S

Columbus Community Clinical Oncology Prg
United States

Columbus NCORP RFA-CA-18-016 3UG1CA189954-11S1 Vanessa A. White, M.P.H.
Rajagopalan, Malolan S

Columbus Community Clinical Oncology Prg
United States

Columbus NCORP RFA-CA-18-016 3UG1CA189954-11S1 Vanessa A. White, M.P.H.
Rajkumar, S Vincent

Mayo Clinic Rochester
United States

Onset and biomarkers for progression of monoclonal gammopathies 5R01CA168762-11 Nicholas Hodges, Ph.D.
Ramanujam, Nirmala

Duke University
United States

Development and Validation of an Artificial-Intelligence-enabled Portable Colposcopy Device for Optimizing Triage Alternatives for HPV-based Cervical Cancer Screening 3U01CA269192-04S1 Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Rao, Chinthalapally V.

University Of Oklahoma Hlth Sciences Ctr
United States

Discovery and Development of Natural Products for Interception of CRC 5UG3CA290310-02 Kajal Biswas, Ph.D.